
Revolution Medicines, Inc. Common Stock
RVMD
RVMD: Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
moreShow RVMD Financials
Recent trades of RVMD by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by RVMD's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric shp2 inhibitors Aug. 29, 2023
-
Patent Title: Ras inhibitors Aug. 29, 2023
-
Patent Title: Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors Jul. 18, 2023
-
Patent Title: Ras inhibitors Jul. 04, 2023
-
Patent Title: C26-linked rapamycin analogs as mtor inhibitors Jun. 27, 2023
-
Patent Title: Polycyclic compounds as allosteric shp2 inhibitors Jun. 13, 2023
-
Patent Title: Pyridine compounds as allosteric shp2 inhibitors Jun. 13, 2023
-
Patent Title: 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors May. 30, 2023
-
Patent Title: Identifying new therapeutic agents May. 09, 2023
-
Patent Title: Polycyclic compounds as allosteric shp2 inhibitors Apr. 25, 2023
-
Patent Title: Ras inhibitors Mar. 21, 2023
-
Patent Title: Shp2 inhibitor compositions and methods for treating cancer Mar. 07, 2023
-
Patent Title: Ras inhibitors Jan. 31, 2023
-
Patent Title: C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors Jun. 21, 2022
-
Patent Title: Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a shp2 inhibitor Jan. 11, 2022
-
Patent Title: Bicyclic heteroaryl compounds and uses thereof Nov. 09, 2021
-
Patent Title: Compounds that participate in cooperative binding and uses thereof Jul. 13, 2021
-
Patent Title: Identifying new therapeutic agents Apr. 27, 2021
-
Patent Title: C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors Apr. 20, 2021
-
Patent Title: Methods and reagents for analyzing protein-protein interfaces Mar. 16, 2021
-
Patent Title: 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors Mar. 17, 2020
-
Patent Title: Compounds that participate in cooperative binding and uses thereof Jan. 14, 2020
-
Patent Title: Methods and reagents for analyzing protein-protein interfaces Nov. 05, 2019
Federal grants, loans, and purchases
Followers on RVMD's company Twitter account
Number of mentions of RVMD in WallStreetBets Daily Discussion
Recent insights relating to RVMD
Recent picks made for RVMD stock on CNBC
ETFs with the largest estimated holdings in RVMD
Flights by private jets registered to RVMD